Zoledronic acid-induced severe lymphopenia.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 37322374.
- Also identified by DOI 10.1007/s00198-023-06831-6.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although anemia, thrombocytopenia, and mild lymphopenia have been reported in the acute phase response after zoledronic acid, severe lymphopenia has not been reported. This article describes a case of severe lymphopenia following a 5 mg zoledronic acid infusion administered to treat osteoporosis. Zoledronic acid is used to treat osteoporosis, hypercalcemia, Paget's disease, and solid malignancies, including multiple myeloma, breast cancer, and prostate cancer. An acute phase response can be seen in 42% of patients after zoledronic acid treatment. Acute phase response may be accompanied by short-term spontaneously recovered anemia, thrombocytopenia, and severe lymphopenia.
Medical subject headings
- Osteoporosis
- Thrombocytopenia
- Lymphopenia
- Anemia
- Bone Density Conservation Agents